Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 특이적 T 세포 및 항체, 코로나바이러스 질병 2019(COVID-19) 보호: 전향적 연구Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus analyzed antibody Antibody Response Antibody responses CD4+ CD8+ T cell CD8+ T cells clinical comparable coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 correlated COVID-19 demonstrated ELISPOT enzyme enzyme-linked immunosorbent evaluated flow cytometry followed by fraction Fractions frequencies Frequency healthcare highest IFN-γ IgG immune immune response Immunoglobulin Immunoglobulin G immunoglobulin M individual Infection interferon gamma interleukin interleukin 2 Kaplan-Meier estimator membrane nucleocapsid pandemic positive Probability Prospective PROTECT protective effect question Registration respiratory response SARS-CoV-2 SARS-COV-2 infection Spike protein Spike proteins staining T cell T cells T-cell T-cell and antibody responses T-cell Response T-cell responses the SARS-CoV-2 virus virus-specific antibodies Virus-specific IgG were infected with infection [DOI] 10.1093/cid/ciac278 PMC 바로가기 [Article Type] Article
Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-γ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination감염 또는 백신 접종 후 T-세포 반응의 간단한 검출을 위한 표준화된 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 인터페론-γ 방출 분석의 임상 성능Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, 치료기술, [키워드] 19 2 95% confidence interval Accuracy acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 best Cell cell response Chain Reaction clinical convalescent Convalescent patients coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 CoV COVID COVID-19 dependent on detection disease severity Euroimmun evaluated Follow-up Germany healthy IFN-γ IFN-γ response IFN-γ responses IGRA immune response individual Infection interferon interferon-γ magnitude Mild disease mild infections Neutralizing antibodies neutralizing antibody Patient performance polymerase chain reaction positive Primary infection Prospective Study Quantitative reference standard Release respiratory response reverse transcription Reverse transcription-polymerase chain reaction SARS SARS-CoV-2 SARS-COV-2 infection sensitivity serological serological test Serological tests serology severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe COVID-19 severity severity of illness simple specificity subject subjects T T-cell T-cell Response uninfected vaccination was measured Whole blood with mild disease γ release assay. [DOI] 10.1093/cid/ciab1021 PMC 바로가기 [Article Type] Article
Reduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in Chile칠레의 면역 저하 환자 집단에서 비활성화된 중증 급성 호흡기 증후군 코로나바이러스 2 백신에 대한 면역 반응 감소Article Published on 2022-08-242022-09-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, [키워드] acute respiratory syndrome anti-SARS-CoV-2 antibody Autoimmune Cancer Cell clinical concentrations conducted control group controls CoronaVac coronavirus coronavirus 2 COVID-19 dose Enrollment evaluate groups HIV HIV group Human immunodeficiency virus humoral immune response Immunocompromised Immunocompromised patient immunocompromising condition Immunoglobulin Inactivated vaccine Infection interferon γ median Neutralizing activity not differ not significant participant patients prospective cohort study receiving Red reduce respiratory response rheumatic disease SARS-CoV-2 significantly solid organ transplant solid tumor T cell T-cell Response Trial Vaccination strategy Vaccine vulnerable patients [DOI] 10.1093/cid/ciac167 PMC 바로가기 [Article Type] Article
Serum peptidome profiles immune response of COVID-19 Vaccine administrationArticle Published on 2022-08-242022-11-15 Journal: Frontiers in Immunology [Category] SARS, 바이오마커, 진단, [키워드] activated acute respiratory syndrome administration Analysis analyzed Antigen Biomarker C1q caused CD59 CD99 Cellular immune response clinical trials collected Complete CoronaVac coronavirus Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine Efficacy Evidence glycoprotein help hemoglobin humoral immune immune response immunization immunogenicity analysis individual information Laboratory linear Logistic regression MALDI-TOF membrane protein NAb neutralizing antibody pandemic participant peptide peptides Peptidome performed Platelet profile Protein provided random receiving receptor reported Research SARS-CoV-2 serum serum sample Significant statistical analysis subunits Support SVM vaccination Vaccine Vaccines [DOI] 10.3389/fimmu.2022.956369 PMC 바로가기
Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial6세 이상의 건강한 참가자를 대상으로 한 상동 프라임-부스트 요법을 사용한 재조합 아데노바이러스 5형 벡터 코로나바이러스 질병 2019(COVID-19) 백신의 안전성 및 면역원성: 무작위, 이중 맹검, 위약 대조, 2b상 시험Randomized Controlled Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] 임상, 진단, 치료기술, [키워드] Ad5-vectored COVID-19 vaccine Adenovirus adenovirus type-5-vectored COVID-19 vaccine Adults Adverse adverse events antibody Antibody Response boost children clinical Cohort coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine dose double-blind elicited ELISA enrolled enzyme enzyme-linked immunosorbent assay event geometric mean geometric mean titer geometric mean titers GMT GMTs healthy homologous homologous prime immune response immune responses immunogenicity increasing age MIN neutralizing antibody participant phase phase 2b trial. Placebo placebo-controlled trial prime-boost regimen pseudovirus neutralizing antibody Randomized RBD receiving Receptor binding domain recombinant recombinant adenovirus robust Safe Safety SARS-CoV-2 single dose tolerable Trial vaccination Vaccine Viral viral particle [DOI] 10.1093/cid/ciab845 PMC 바로가기 [Article Type] Randomized Controlled Trial
Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2) 백신 BNT162b2 또는 mRNA-1273 투여 후 면역저하 환자의 항체 반응: 무작위 대조 시험Randomized Controlled Trial Published on 2022-08-242022-09-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, 진단, [키워드] 1:1 95% confidence interval acute respiratory syndrome addition Antibody Response BNT162b2 Cohort Controlled coronavirus coronavirus 2 Cutoff Efficacy Elecsy first vaccination had no HIV Human immunodeficiency virus immune response immunoassay Immunocompromised patient Immunocompromised patients infections intention-to-treat analysis kidney lung Moderna mRNA-1273 Open-label organ Organ transplant Patient Pfizer-BioNTech platform Platform trial PLWH Prevent primary endpoint proportion Protein Randomized randomized clinical trial Randomized controlled trial Receptor binding domain recipient respiratory response SARS-CoV-2 SARS-CoV-2 spike second vaccination solid organ transplant the antibody response Transplant Vaccine was measured [DOI] 10.1093/cid/ciac169 PMC 바로가기 [Article Type] Randomized Controlled Trial
A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein VaccineArticle Published on 2022-08-242022-11-15 Journal: Viruses [Category] SARS, 진단, [키워드] activate acute respiratory syndrome adjuvant adjuvants aluminum China Combination coronavirus CpG effective elevated Emergency use authorization Genome hydroxide immune immune response immunogenicity Innate immunity levels of antibody mice Neutralizing antibody titer novel novel adjuvant omicron Protein RBD Receptor binding domain recombinant recombinant RBD protein Research SARS-CoV-2 SARS-CoV-2 recombinant protein vaccine signaling pathway single-stranded single-stranded RNA-based adjuvant. subunit Th1 Th2 the antibody response the SARS-CoV-2 Vaccine was used ZF2001 [DOI] 10.3390/v14091854 PMC 바로가기
Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational StudyPost-mRNA 예방접종 후 중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2) 면역글로불린 G(IgG) 농도 및 HIV(인간면역결핍바이러스)에 의한 대리바이러스 중화시험 반응의 차이 백신의 상태 및 유형: 일치된 사례-대조군 관찰 공부하다Observational Study Published on 2022-08-242022-09-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, 진단, [키워드] acute respiratory syndrome BNT162b2 vaccine CD4+ T-cell coronavirus coronavirus 2 COVID-19 difference HIV Human Human immunodeficiency virus IgG immune immune response Immunoglobulin Immunoglobulin G Matched mRNA vaccination PLWH respiratory response SARS-CoV-2 status surrogate Test Type vaccination vaccine dose virus neutralization test [DOI] 10.1093/cid/ciab1009 PMC 바로가기 [Article Type] Observational Study
Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count현재 CD4 T-림프구 수를 기반으로 항레트로바이러스 치료를 받고 있는 인간 면역결핍 바이러스에 감염된 사람들의 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 mRNA 백신 접종으로 유도된 체액 및 세포 면역 반응Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, 치료기술, [키워드] 2 vaccine Against AIDS anti ART BNT162b2 booster dose CD4 CD4 T-cell cell-mediated immune comparable confounders control group controls coronavirus 2 count CoV current detectable elicited HCDR HCW HCWs healthcare worker HIV HIV-negative Human IFN-γ immune response immunogenicity magnitude mRNA mRNA-1273 NAb NAbs Neutralizing Neutralizing antibodies parameter parameters participant PLWH predicted RBD-binding antibody RBD-binding IgG receiving reduced respiratory response SARS SARS-CoV-2 SARS-CoV-2 neutralizing antibodies SARS-CoV-2 neutralizing antibody SARS-CoV-2 vaccination SARS-CoV-2 vaccine significantly significantly lower stratified T-lymphocyte titre were measured were used [DOI] 10.1093/cid/ciac238 PMC 바로가기 [Article Type] Article
Plasma metabolome and cytokine profile reveal glycylproline modulating antibody fading in convalescent COVID-19 patients혈장 대사체 및 사이토카인 프로필은 회복기 COVID-19 환자에서 글리실프롤린 조절 항체 퇴색을 나타냅니다Article Published on 2022-08-232022-09-11 Journal: Proceedings of the National Academy of Sciences of [Category] SARS, 바이오마커, 진단, [키워드] accumulated Accuracy acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 alteration antibody association catalyzed cleavage conducted convalescent convalescent COVID-19 patient convalescent COVID-19 patients convalescent patient Convalescent patients coronavirus COVID-19 COVID-19 convalescent patients COVID-19 pandemic cytokine cytokine profile cytokine profiling Cytokines demonstrated dipeptide dipeptidyl peptidase Dipeptidyl peptidase 4 domain down-regulate DPP4 experiment feature Feature selection glycylproline healthy healthy subjects IL-12p40 immune response immune responses individual inhibitor inhibitory effect Inhibitory effects M-CSF machine-learning mechanism metabolite metabolites metabolome metabolomics mice modulating neutralizing antibody outcome peptide plasma Plasma cytokine product public health Quantitative respiratory SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination severe acute respiratory syndrome Coronavirus sitagliptin suppresse therapeutic Treatment vaccination Vaccination strategy with COVID-19 [DOI] 10.1073/pnas.2117089119 PMC 바로가기 [Article Type] Article